All In Biotech

Drug Trial Radar · NCT07585266

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Aug 30, 2032

Study completion Sep 28, 2032

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.

Conditions

  • Gastrointestinal Stromal Neoplasms

Interventions

  • VelzatinibDrug

    Velzatinib will be administered

  • ImatinibDrug

    Imatinib will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)Time frame: Up to approximately 74 months

Locations

93 sites in 20 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Scottsdale, Arizona · Recruiting

  • GSK Investigational Site

    San Francisco, California · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Bethesda, Maryland · Recruiting

  • GSK Investigational Site

    Kansas City, Missouri · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Durham, North Carolina · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Knoxville, Tennessee · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Seattle, Washington · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Capital Federal, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad autOnoma de Bueno, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina · Recruiting

  • GSK Investigational Site

    Melbourne, Victoria, Australia · Recruiting

  • GSK Investigational Site

    Barretos, Brazil · Recruiting

  • GSK Investigational Site

    Florianópolis, Brazil · Recruiting

  • GSK Investigational Site

    Natal, Brazil · Recruiting

  • GSK Investigational Site

    Porto Alegre, Brazil · Recruiting

  • GSK Investigational Site

    Vitória, Brazil · Recruiting

  • GSK Investigational Site

    Teresina, Piauí, Brazil · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Beijing, China · Recruiting

  • GSK Investigational Site

    Chengdu, China · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Hangzhou, China · Recruiting

  • GSK Investigational Site

    Jinan, China · Recruiting

  • GSK Investigational Site

    Nanjing, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Wuhan, China · Recruiting

  • GSK Investigational Site

    Zhengzhou, China · Recruiting

  • GSK Investigational Site

    Helsinki, Finland · Recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.